Oncotarget

Clinical Research Papers:

Clinical benefit of continuing crizotinib therapy after initial disease progression in Chinese patients with advanced ALK-rearranged non-small-cell lung cancer

Xiangchan Hong, Qi Chen, Lingyu Ding, Ying Liang, Ningning Zhou, Wenfeng Fang, Xinru Chen and Haiying Wu _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:41631-41640. https://doi.org/10.18632/oncotarget.15892

Metrics: PDF 809 views  |   HTML 1279 views  |   ?  


Abstract

Xiangchan Hong1, Qi Chen2, Lingyu Ding3, Ying Liang1, Ningning Zhou1,Wenfeng Fang1, Xinru Chen1 and Haiying Wu1

1 Department of Medical Oncology, Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, China

2 Department of Oncology, The First Affiliated Hospital of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou, China

3 Department of Medical Oncology, Hangzhou Cancer Hospital, Hangzhou, China

Correspondence to:

Haiying Wu, email:

Keywords: non-small-cell lung cancer, anaplastic lymphoma kinase, crizotinib, treatment beyond disease progression, progression-free survival

Received: October 20, 2016 Accepted: February 22, 2017 Published: March 04, 2017

Abstract

Purpose: Although most patients with ALK-positive non‒small-cell lung cancer (NSCLC) who benefit from treatment with crizotinib ultimately develop progressive disease (PD), continuing crizotinb beyond the initial PD (CBPD) in these patients may be beneficial. In this study, we investigated whether Chinese patients with advanced ALK-positive NSCLC benefit from CBPD, and whether any factors are predictive of a longer post-initial progression-free survival time (PFS2).

Materials and Methods: Data on 33 patients with ALK-positive NSCLC who achieved disease control with crizotinib were analyzed retrospectively. The impact of continued crizotinib therapy on the patients’ PFS2 time was assessed after adjusting for potential confounding factors.

Results: With initial crizotinib therapy, the objective response rate (ORR) and median PFS time (PFS1) in the 33 patients were 63.6% and 8.6 months, respectively. With continued crizotinib therapy after documentation of PD, the median PFS2 for all 33 patients was 16 weeks, and in those with CNS progression but systemic disease control it was 30 weeks. Patients who received local therapy after disease progression had a significantly longer PFS2 compared with those who did not (P = 0.039). Multivariable Cox regression analysis showed that the PFS1 with initial crizotinib treatment and local therapy were independent predictors of PFS2.

Discussion: This study provides further evidence of the benefit of continuing crizotinib therapy in Chinese patients with progressive ALK-positive NSCLC. Patients with a longer PFS1 and those who received local brain therapy would have a longer period of continuing crizotinib.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15892